Differential prognostic impact of UPA and pai-1 in colon and rectal cancer

Tumor Biology

Volumn 30, Issue 4, 2009, Pages 210-220

  Langenskiöld, Marcus ^a,b   Holmdahl, Lena ^b   Angenete, Eva ^b   Falk, Peter ^b   Nordgren, Svante ^b   Ivarsson, Marie Louise ^b,c  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

^c Kungsbacka Hospital   (Sweden)

Author keywords

Colorectal; Mucosa; Prognosis; Survival; Tumour stage

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ADULT; AGED; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECTUM CANCER;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGNOSIS; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 70349261106     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000239796     Document Type: Article

References (44)

1. Macdonald JS: Adjuvant therapy of colon cancer. CA Cancer J Clin 1999; 49: 202-219.
2. Graziano F, Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol 2003; 14: 1026-1038.
3. Zeng ZS, Cohen AM, Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 1999; 20: 749-755.
4. Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
5. Lijnen HR: Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 2005; 3: 35-45.
6. Lund LR, Green KA, Stoop AA, Ploug M, Almholt K, Lilla J, Nielsen BS, Christensen IJ, Craik CS, Werb Z, Dano K, Romer J: Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. Embo J 2006; 25: 2686-2697.
7. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N: Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999; 71: 130-135.
8. Yang JL, Seetoo D, Wang Y, Ranson M, Berney CR, Ham JM, Russell PJ, Crowe PJ: Urokinase- type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancerspecific survival and potential therapeutic targets. Int J Cancer 2000; 89: 431-439.
9. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl- Hansen J: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
10. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869-874.
11. Terada H, Urano T, Konno H: Association of interleukin-8 and plasminogen activator system in the progression of colorectal cancer. Eur Surg Res 2005; 37: 166-172.
12. Morgan H, Hill PA: Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int 2005; 5: 1.
13. Potempa J, Korzus E, Travis J: The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-15960.
14. Binder BR, Mihaly J: The plasminogen activator inhibitor 'paradox' in cancer. Immunol Lett 2008; 118: 116-124.
15. Kwaan HC, Wang J, Svoboda K, Declerck PJ: Plasminogen activator inhibitor 1 may promote tumour growth through inhibition of apoptosis. Br J Cancer 2000; 82: 1702-1708.
16. Chazaud B, Ricoux R, Christov C, Plonquet A, Gherardi RK, Barlovatz-Meimon G: Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am J Pathol 2002; 160: 237-246.
17. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-928.
18. Bajou K, Maillard C, Jost M, Lijnen RH, Gils A, Declerck P, Carmeliet P, Foidart JM, Noel A: Host-derived plasminogen activator inhibitor- 1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 2004; 23: 6986-6990.
19. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH: Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006; 6: 211.
20. Langenskiold M, Holmdahl L, Falk P, Angenete E, Ivarsson ML: Increased TGF- 1 protein expression in patients with advanced colorectal cancer. J Surg Oncol 2008; 97: 409-415.
21. Kushiyama Y, Fukuda R, Suetsugu H, Kazumori H, Ishihara S, Adachi K, Kinoshita Y: Site-dependent production of transforming growth factor- 1 in colonic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 2000; 136: 201-208.
22. Takahashi Y, Onda M, Tanaka N, Seya T: Establishment and characterization of two new rectal neuroendocrine cell carcinoma cell lines. Digestion 2000; 62: 262-270.
23. Beahrs OH HD, Hutter RVP, et al: AJCC Manual for Staging of Cancer, ed 4. Philadelphia, Lippincott, 1992.
24. Holmdahl L, Kotseos K, Bergstrom M, Falk P, Ivarsson ML, Chegini N: Overproduction of transforming growth factor- 1 (TGF- 1) is associated with adhesion formation and peritoneal fibrinolytic impairment. Surgery 2001; 129: 626-632.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
26. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N: Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7: 617-623. (Pubitemid 30708485)
27. Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S: Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer 1999; 86: 2602-2611.
28. Papadopoulou S, Scorilas A, Yotis J, Arnogianaki N, Plataniotis G, Agnanti N, Talieri M: Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas. Tumour Biol 2002; 23: 170-178.
29. Baker EA, Bergin FG, Leaper DJ: Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression. Mol Pathol 2000; 53: 307-312.
30. Herszenyi L, Plebani M, Carraro P, De Paoli M, Roveroni G, Cardin R, Tulassay Z, Naccarato R, Farinati F: The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999; 86: 1135-1142.
31. Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML: uPA and PAI-1 in rectal cancer-relationship to radiotherapy and clinical outcome. J Surg Res 2009; 153: 46-53.
32. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL: Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82: 184-193.
33. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, et al: Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-4071.
34. Fujii T, Obara T, Tanno S, Ura H, Kohgo Y: Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology 1999; 46: 2299-2308.
35. Fernebro E, Madsen RR, Ferno M, Brunner N, Bendahl P, Christensen IJ, Johnson A, Nilbert M: Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients. Eur J Cancer 2001; 37: 486-491.
36. Derwinger K, Carlsson G, Gustavsson B: Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol 2007; 33: 849-853.
37. Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP, Larsson L, Gustavsson B: Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003; 9: 6012-6019.
38. Gervaz P, Bucher P, Morel P: Two colons - two cancers: paradigm shift and clinical implications. J Surg Oncol 2004; 88: 261-266.
39. Benraad TJ, Geurts-Moespot J, Grondahl- Hansen J, Schmitt M, Heuvel JJ, de Witte JH, Foekens JA, Leake RE, Brunner N, Sweep CG: Immunoassays (ELISA) of urokinasetype plasminogen activator (uPA): report of an EORTC/BIOMED-1 workshop. Eur J Cancer 1996; 32A:1371-1381.
40. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ: Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-791.
41. Takeha S, Fujiyama Y, Bamba T, Sorsa T, Nagura H, Ohtani H: Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect. Jpn J Cancer Res 1997; 88: 72-81.
42. Miseljic S, Galandiuk S, Myers SD, Wittliff JL: Expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in colon disease. J Clin Lab Anal 1995; 9: 413-417.
43. Solberg A, Holmdahl L, Falk P, Willen R, Palmgren I, Ivarsson ML: Progress of tissue injury in appendicitis involves the serine proteases uPA and PAI-1. Scand J Gastroenterol 2009; 44: 579-584.
44. Bingle L, Brown NJ, Lewis CE: The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol 2002; 196: 254-265.